“…For the initial screening of cultured MSCs from the nonhuman species, we used a panel of 43 mAb that contained the following commercially available mAb against human CD3,13,14,19,29,31,34,44,45,49,55,71,73,90,117,146, HLA-ABC, HLA-DR, Sca-1 [45] (Becton Dickinson), CD105 (Ancell Corp.), CD235a (Dako), CD271 (Clone 20.4 against low-affinity nerve growth factor receptor-allophycocyanin; Miltenyi Biotec), ALP (clone B4-78-c; Hybridoma Bank), KDR (R&D Systems), SSEA-4 (clone MC-813-70; Hybridoma Bank), W8B2 against human MSCs antigen-1 (MSCA-1= W8B2-phycoerythrin (PE); Biolegend), W4A5 against MSCs, and neural progenitor cells (W4A5-PE; Biolegend). Additionally, we used a series of mAb that showed reactivity with the CD271 þ subpopulation in human BM with putative MSCs specificity [46].…”